Having trouble accessing articles? Reset your cache.

Targeted Bcl-XL degrader identified to treat ALL, TNBC and SCLC

DISEASE CATEGORY: Cancer

INDICATION: Acute lymphoblastic leukemia (ALL); breast cancer; small cell lung cancer

A University of Florida team led by Dialectic Therapeutics Inc. co-founders Guangrong Zheng and Daohong Zhou showed

Read the full 298 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE